Beclometasone/Formoterol/Glycopyrrolate

DRUG3 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

COPDChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.

CompletedNCT02040597

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease (COPD)

Start: 2014-01-31End: 2015-04-30Updated: 2021-10-29

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients

CompletedNCT02119234

Chiesi Farmaceutici S.p.A.COPD

Start: 2014-03-31End: 2015-02-28Updated: 2021-10-29

Phase 3

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

CompletedNCT01917331

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2014-03-31End: 2016-03-31Updated: 2021-10-29

Related Papers

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

2020-06-0510 citations

<p>Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA</p>

International Journal of COPD2019-02-0121 citations

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis.

2018-09-0612 citations

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

2016-09-01280 citations